CS 23546
Alternative Names: CS-23546Latest Information Update: 25 Apr 2024
At a glance
- Originator Chipscreen Biosciences
- Class Antineoplastics; Biphenyl compounds; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
- Preclinical Immunological disorders
Most Recent Events
- 27 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease) in China (PO) (NCT06245122)
- 07 Feb 2024 Chipscreen Biosciences plans phase I trial in Cancer (Late-stage disease, Unresectable) in February 2024 in China (PO) (NCT06245122)
- 27 Oct 2021 Chipscreen Biosciences plans to file IND application in year 2022